Sign inCreate account

Report workspace tools

NCT03415477COMPLETEDanonymous

Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts

Sponsor

Source record

Peking University People's Hospital

Phase

Source record

PHASE1

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Denosumab (Xgeva)

Indication / condition

AI-normalized

Bone Cyst Aneurysmal

Intervention

Source record

Denosumab (Xgeva)

Source & freshness

Source record

NCT ID

NCT03415477

Original source

ClinicalTrials.gov

Source last updated

Jan 30, 2018

Ingested at

May 21, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03415477

Title

Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts

Sponsor

Peking University People's Hospital

Status

COMPLETED

Phase

PHASE1

Condition raw

Bone Cyst Aneurysmal, Pathological Fracture, Recurrent Disease, Refractory Tumor

Condition normalized

Bone Cyst Aneurysmal, Pathological Fracture, Recurrent Disease, Refractory Tumor

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Denosumab (Xgeva)

Target normalized

Denosumab (Xgeva)

Interventions

Denosumab (Xgeva)

Public preview

Source record

The efficacy of traditional therapeutic approaches for aneurysmal bone cysts (ABC), such as surgery, embolization, sclerotherapy and radiotherapy, are often compromised for lesions in axial skeletons and adolescents complicated with pathological fracture. Therefore, denosumab, a new drug that has been successfully used in giant cell tumor of bone but has seldom used in ABC, was used to treat ABC in this trial.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03415477

Status

COMPLETED

Phase

PHASE1

Sponsor

Peking University People's Hospital

Executive brief

Investment-Ready Snapshot

The efficacy of traditional therapeutic approaches for aneurysmal bone cysts (ABC), such as surgery, embolization, sclerotherapy and radiotherapy, are often compromised for lesions in axial skeletons and adolescents complicated with pathological fracture. Therefore, denosumab, a new drug that has been successfully used in giant cell tumor of bone but has seldom used in ABC, was used to treat ABC in this trial.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 30, 2018
Internal syncMay 23, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03415477

Indication

Bone Cyst Aneurysmal

Modality

monoclonal antibody

Target

Denosumab (Xgeva)

Intervention

Denosumab (Xgeva)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.